Status:

COMPLETED

Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses

Lead Sponsor:

Johnson & Johnson Vision Care, Inc.

Conditions:

Visual Acuity

Eligibility:

FEMALE

18-29 years

Phase:

NA

Brief Summary

This will be a randomized, double-masked, bilateral, cross-over, 2 treatment by 2 period dispensing study. There will be 4 visits. There will be a 2 to 5 day washout period between treatments.

Eligibility Criteria

Inclusion

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study:
  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form
  • Females between 18 and 29 (inclusive) years of age at the time of screening
  • Appear able and willing to adhere to the instructions set forth in this clinical protocol (i.e. willing to wear only the study lenses and not use habitual lenses during the dispensing periods)
  • Be a current soft contact lens wearer in both eyes with a minimum of 6 hours/day and 5 days/week over the last month by self-report
  • Be a current wearer of cosmetic/circle lenses in the last 6 months, by self-report.
  • The subject must be willing to be photographed and/or video-taped
  • The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 D to -6.00 D (inclusive) in each eye
  • The subject's refractive cylinder must be less than or equal to 0.75 D (inclusive) in each eye
  • Have spherical best corrected visual acuity of 20/25 or better in each eye.

Exclusion

  • Currently pregnant or lactating
  • Any systemic disease (eg, Sjögren's Syndrome), allergies, infectious disease (eg, hepatitis, tuberculosis), contagious immunosuppressive diseases (eg, HIV), autoimmune disease (eg, rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study (at the investigators discretion)
  • Use of systemic medications (eg, chronic steroid use) that are known to interfere with contact lens wear (at the investigators discretion)
  • Any previous or planned (during the study) ocular surgery (eg, radial keratotomy, PRK, LASIK, etc.).
  • Any previous history or signs of a contact lens-related corneal inflammatory event (eg, past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear (at the investigators discretion).
  • Participation in any contact lens or lens care product clinical trial within seven (7) days prior to study enrollment
  • Employee or family members of clinical site (eg, Investigator, Coordinator, Technician)
  • Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion (at the investigators discretion)
  • Clinically significant (Grade 3 or 4 on FDA scale) tarsal abnormalities, bulbar injection, corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.

Key Trial Info

Start Date :

August 13 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 15 2020

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT04529109

Start Date

August 13 2020

End Date

September 15 2020

Last Update

November 24 2021

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Stam & Associates Eye Care

Jacksonville, Florida, United States, 32256

2

Frazier Vision, Inc

Tyler, Texas, United States, 75703

3

Vital Eyecare Center

Mong Kok, Kowloon, Hong Kong

4

Sight Enhancement Center

Yau Ma Tei, Kowloon, Hong Kong